These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3957490)

  • 1. The effect of activated charcoal on the bioavailability of piroxicam in man.
    Laufen H; Leitold M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):48-52. PubMed ID: 3957490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of piroxicam in man.
    Hobbs DC
    Eur J Rheumatol Inflamm; 1983; 6(1):46-55. PubMed ID: 6861813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and relative bioavailability of vinylbital in man after oral and rectal administration.
    Breimer DD; de Boer AG
    Arzneimittelforschung; 1976; 26(3):448-54. PubMed ID: 989344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.
    Stass H; Kubitza D; Möller JG; Delesen H
    Br J Clin Pharmacol; 2005 May; 59(5):536-41. PubMed ID: 15842551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral charcoal and urine pH on sotalol pharmacokinetics.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Aug; 22(8):441-6. PubMed ID: 6092287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):326-32. PubMed ID: 3015809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of droxicam in rat and dog.
    Esteve A; Martínez L; Roser R; Sagarra R
    Methods Find Exp Clin Pharmacol; 1986 Jul; 8(7):423-9. PubMed ID: 3762266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal dialysis of disopyramide in healthy subjects.
    Arimori K; Kawano H; Nakano M
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):280-4. PubMed ID: 2737797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of flecainide resorption by activated charcoal].
    Nitsch J; Köhler U; Lüderitz B
    Z Kardiol; 1987 May; 76(5):289-91. PubMed ID: 3113085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of activated charcoal on rifampicin absorption in man.
    Orisakwe OE; Dioka CE; Okpogba AN; Orish CN; Ofoefule SI
    Tokai J Exp Clin Med; 1996 Feb; 21(1):51-4. PubMed ID: 9239805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics.
    Kärkkäinen S; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):219-25. PubMed ID: 2987139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.
    Lapatto-Reiniluoto O; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2001 Sep; 70(3):255-60. PubMed ID: 11557913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam in rodents and in man.
    Schiantarelli P; Acerbi D; Bovis G
    Arzneimittelforschung; 1981; 31(1):92-7. PubMed ID: 6971114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profiles of two tablet formulations of piroxicam.
    Rasetti-Escargueil C; Grangé V
    Int J Pharm; 2005 May; 295(1-2):129-34. PubMed ID: 15847998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
    Kakuda TN; Falcon RW
    Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.